Skip Navigation

European Heart Journal 2001 22(24):2233-2242; doi:10.1053/euhj.2001.2612
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kamath, S.
Right arrow Articles by Lip, G.Y.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamath, S.
Right arrow Articles by Lip, G.Y.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review

Platelets and atrial fibrillation

S. Kamath, A.D. Blann and G.Y.H. Lipf1

Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, U.K.

revised January 16, 2001; accepted January 17, 2001

Key Words: atrial fibrillation, platelets, antiplatelet therapy.

f1 Correspondence: Professor G. Y. H. Lip, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, U.K.

References

  1. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet. 1995;346:1313–1314[CrossRef][Web of Science][Medline]
  2. Lip GYH, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995;73:527–533[Abstract/Free Full Text]
  3. Packham MA. Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol. 1994;72:278–284[Web of Science][Medline]
  4. Kunicki TJ. Platelet membrane glycoproteins and their function: an overview. Blut. 1989;59:30–34[CrossRef][Web of Science][Medline]
  5. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979;64:1393–1401[Web of Science][Medline]
  6. Plow EF, Marguerie GA. Induction of the fibrinogen receptor on human platelets by epinephrine and the combination of epinephrine and ADP. J Biol Chem. 1980;255:10971–10977[Abstract/Free Full Text]
  7. Kinlough-Rathbone RL, Mustard JF, Packham MA, Perry DW, Reimers JH, Cazenave JP. Properties of washed human platelets. Thromb Haemost. 1977;37:291–308[Web of Science][Medline]
  8. Colman RW. Platelet receptors. Hematol Oncol Clin North Am. 1990;4:27–42[Web of Science][Medline]
  9. Verstraeten L, Francois P, Dinant JP. The physiology of primary hemostasis. J Pharm Belg. 1989;44:302–307[Web of Science][Medline]
  10. Seiss W. Molecular mechanisms of platelet activation. Physiol Rev. 1989;69:58–178[Free Full Text]
  11. Mustard JF, Packham MA. The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thrombosis Diathesis Haemorrhage. 1975;33:444–456
  12. Mustard JF, Packham MA, Rowsell HX, Jorgensen L. The role of thrombogenic factors in atherosclerosis. Ann N York Acad Sci. 1968;149:848–859[CrossRef][Web of Science][Medline]
  13. Cahill MR, Newland AC. Platelet activation in coronary artery disease. Br J Biomed Sci. 1993;50:221–234[Web of Science][Medline]
  14. Grau AJ, Ruf A, Vogt A. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost. 1998;80:298–301[Web of Science][Medline]
  15. Minamino T, Kitakaze M, Sato H. Plasma adenosine levels and platelet activation in patients with atrial fibrillation. Am J Cardiol. 1999;83:194–198[CrossRef][Web of Science][Medline]
  16. Sevush S, Jy W, Horstman LL, Mao WW, Kolodyn L, Ahn YS. Platelet activation in Alzheimer Disease. Arch Neurol. 1998;55:530–536[Abstract/Free Full Text]
  17. Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology. 1994;106:840–845[Web of Science][Medline]
  18. De Boer AC, Han P, Turpie AG, Butt R, Zielinsky A, Genton E. Plasma and urine beta thromboglobulin concentration in patients with deep vein thrombosis. Blood. 1981;58:693–698[Abstract/Free Full Text]
  19. Tschoepe D, Roesen P, Esser J. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991;17:433–438[Web of Science][Medline]
  20. Maly J, Pecka M, Vodckova L. Changes in the activity of thrombocytes by smoking. Sb Ved Pr Lek Fak Karlovy University Hradci Kralove. 1990;33:325–333
  21. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol. 1987;157:1042–1048[Web of Science][Medline]
  22. Gabassov VA, Popov EG, Gavrilov I Iu, Pozin Ela, Markosian RA. New methodical approach to the study of platelet aggregation in vitro. Biull Eksp Biol Med. 1989;108:437–440[Medline]
  23. FitzGerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1988;77:142–150[Abstract/Free Full Text]
  24. Corash L. Measurement of platelet activation by fluorescence-activated flow cytometry. Blood Cells. 1990;16:97–106[Web of Science][Medline]
  25. Chen YC, Wu KK. A comparison of methods for the study of platelet hyperfunction in thromboembolic disorders. Br J Haematol. 1980;46:263–268[Web of Science][Medline]
  26. Ikeda U, Yamamoto K, Shimada K. Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation and cardiomyopathy. Clin Cardiol. 1997;20:7–10[Web of Science][Medline]
  27. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-Selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost. 1997;77:1077–1080[Web of Science][Medline]
  28. Wipf JE, Lipsky BA. Atrial fibrillation. Thromboembolic risk and indications for anticoagulation. Arch Intern Med. 1990;150:1598–1603[Abstract/Free Full Text]
  29. Kranidis A, Koulouris S, Anthopoulos L. Clinical implications of left atrial spontaneous echo contrast in mitral valve disease. J Heart Valve Dis. 1993;2:267–272[Medline]
  30. Sherman DG, Dyken ML, Fisher M, Harrison MJG, Hart RG. Antithrombotic therapy for cerebrovascular disorders. Chest. 1989;95:140S–155S[Free Full Text]
  31. Beppu S, Park YD, Sakakibara H, Nagata S, Numura Y. Clinical features of intracardiac thrombosis based on echocardiographic observation. Jpn Circ J. 1984;48:75–82[Medline]
  32. Kunishima S, Hattori M, Kobayashi S. Activation and destruction of platelets in patients with rheumatic heart disease. Eur Heart J. 1994;15:335–338[Abstract/Free Full Text]
  33. Kataoka H, Yano S, Mikuriya Y. Relationship of mitral valve area to hemostatic condition in rheumatic mitral stenosis. J Cardiol. 1994;24:387–395[Medline]
  34. Goldsmith I, Li Saw Hee FL, Blann AD, Lip GYH. Increased platelet activation and endothelial dysfunction in patients immediately following percutaneous balloon mitral valvuloplasty. Clin Cardiol. 2000;23:587–590[Web of Science][Medline]
  35. Khatouri A, Kendoussi M, Elyounassi B, Nazzi M, Zbir E, Hamnai A. Predictive factors of thrombembolic complications in mitral stenosis in sinus rhythm. Ann Cardiol Agneiol. 1996;45:573–576
  36. Leung DY, Black IW, Cranney GB, McCredie RM, Hopkins AP, Walsh WF. Resolution of left atrial spontaneous echocardiographic contrast after percutaneous mitral valvuloplasty: implications for thromboembolic risk. Am Heart J. 1995;129:65–70[CrossRef][Web of Science][Medline]
  37. Barnett HJ, Boughner DR, Taylor DW, Cooper PE, Kostuk WJ, Nichol PM. Further evidence relating mitral valve prolapse to cerebral ischemic events. N Engl J Med. 1980;302:139–144[Abstract]
  38. Jeresaty RM. Mitral valve prolapse. An update. JAMA. 1985;254:793–795[Abstract/Free Full Text]
  39. Lewis RP. Cerebral embolism in mitral valve prolapse. Boudoulas H, Wooley CF. Mitral valve prolapse and mitral valve prolapse syndrome. Mount Kisco: Future Publishing; 1988. p. 289–298
  40. Tse HF, Lau CP, Cheng G. Relation between mitral regurgitation and platelet activation. J Am Coll Cardiol. 1997;30:1813–1818[Abstract]
  41. Martini F, Zuppiroli A, Gori A. Platelet and blood clotting Activation in patients with mitral valve prolapse. Thromb Res. 1996;83:299–306[CrossRef][Web of Science][Medline]
  42. Karatasakis GT, Gotsis AC, Cokkinos DV. Influence of mitral regurgitation on left atrial thrombus and spontaneous echo contrast in patients with rheumatic mitral valve disease. Am J Cardiol. 1995;76:279–281[CrossRef][Web of Science][Medline]
  43. Hwaang JJ, Shyu KG, Hsu KL, Chen JJ, Kuan P, Lien WP. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast formation but not against systemic embolism. Chest. 1994;106:8–12[Abstract/Free Full Text]
  44. Movsowitz C, Movsowitz HD, Jacobs LE, Meyerowitz CB, Podolsky LA, Kotler MN. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast and thrombus as assessed by transesophageal echocardiography. J Am Soc Echocardiography. 1993;6:107–114[Medline]
  45. Nakagami H, Yamamoto K, Ikeda U, Mitsuhashi T, Goto T, Shimada K. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J. 1998;136:528–532[CrossRef][Web of Science][Medline]
  46. Maze SS, Kotler MN, Parry WR. Flow characteristics in the dilated left ventricle with thrombus: qualitative and quantitative Doppler analysis. J Am Coll Cardiol. 1989;13:873–881[Abstract]
  47. Goldsmith I, Blann AD, Patel RL, Lip GYH. Reduced indices of left atrial hypercoagulability in patients with severe mitral regurgitation. Am J Cardiol. 2000;86:234–236[CrossRef][Web of Science][Medline]
  48. Kaul H, Gutzweiller JP, Schnedier K, Dirsch O, Hausermann M. Aortic valve stenosis as a cause of major systemic embolism—a case report. Angiology. 1998;49:231–234[Web of Science][Medline]
  49. Goldsmith I, Blann AD, Patel RL, Lip GYH. Plasma fibrinogen, soluble P-selectin and von Willebrand factor in aortic valve disease: evidence for abnormal haemorheology, platelet activation and endothelial dysfunction. Heart. 2000;83:577–578[Free Full Text]
  50. Yamauchi K, Furui H, Taniguchi N, Sotobata I. Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J. 1986;27:481–487[Medline]
  51. Minamino T, Kitakaze M, Sato H. Plasma levels of nitrite/nitrate and platelet C-GMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol. 1997;17:3191–3195[Abstract/Free Full Text]
  52. Furui H, Taniguchi N, Yamauchi K, Sotobata I, Saito H, Inagaki H. Effects of treadmill exercise on platelet function, blood coagulability and fibrinolytic activity in patients with atrial fibrillation. Jpn Heart J. 1987;28:177–184[Medline]
  53. Li Saw Hee FL, Blann AD, Gibbs CR, Edmunds E, Lip GYH. Effect of exercise on haemostatic markers in patients with chronic atrial fibrillation. Clin Cardiol. 2001;:
  54. Li Saw Hee FL, Blann AD, Lip GYH. A cross-sectional and diurnal study of thrombogenesis amongst subjects with chronic atrial fibrillation. J Am Coll Cardiol. 2000;35:1926–1931[Abstract/Free Full Text]
  55. Shinohara H, Fukuda N, Socki T. Relationship between flow dynamics in the left atrium and hemostatic abnormalities in patients with nonvalvular atrial fibrillation. Jpn Heart J. 1998;39:721–730[Medline]
  56. Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GYH. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J. 2000;140:777–784[CrossRef][Web of Science][Medline]
  57. Li Saw Hee FL, Blann AD, Goldmsith I, Lip GY. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol. 1999;83:1206–1209[CrossRef][Web of Science][Medline]
  58. Peverill RE, Harper RW, Gelman J, Gan TE, Harris G, Smolich JJ. Determinants of increased regional left atrial coagulation activity in patients with mitral stenosis. Circulation. 1996;94:331–339[Abstract/Free Full Text]
  59. Yamamoto K, Ikeda U, Seimo Y. Coagulation activity is increased in the left atrium of patients with Mitral Stenosis. J Am Coll Cardiol. 1995;25:107–112[Abstract]
  60. Pongratz G, Brandt-Pohlmann M, Henncke KH. Platelet activation in embolic and preembolic status of patients with non rheumatic atrial fibrillation. Chest. 1997;111:929–933[Abstract/Free Full Text]
  61. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non rheumatic atrial fibrillation. Heart. 1997;77:407–411[Abstract/Free Full Text]
  62. Minamino T, Kitakaze M, Sanada S. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation. 1998;98:1721–1727[Abstract/Free Full Text]
  63. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in Nonvalvular atrial fibrillation. Stoke. 1990;21:47–51[Abstract/Free Full Text]
  64. Nagao T, Hamamoto M, Kanda A. Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with nonvalvular atrial fibrillation. Stroke. 1995;26:1365–1368[Abstract/Free Full Text]
  65. Sohara H, Miyahar K. Effect of atrial fibrillation on the fibrino-coagulation system study in patients with paroxysmal atrial fibrillation. Jpn Circ J. 1994;58:821–826[Medline]
  66. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time dependent manner: A study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106–112[Abstract]
  67. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med. 1999;131:492–501[Abstract/Free Full Text]
  68. Lip GYH. Thromboprophylaxis in atrial fibrillation. Lancet. 1999;353:1620–1621[CrossRef][Web of Science][Medline]
  69. Lip GYH, Lip PL, Zarifis J. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation. 1996;94:425–431[Abstract/Free Full Text]
  70. Koefoed BG, Feddersen C, Gullov AL, Petersen P. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1+2 in patients with atrial fibrillation. Thromb Haemost. 1997;77:845–848[Web of Science][Medline]
  71. Li Saw Hee FL, Blann AD, Lip GYH. Fixed, lowdose warfarin, aspirin-warfarin combination therapy and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000;31:828–833[Abstract/Free Full Text]
  72. Morocutti C, Amabile G, Fattapposta F. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stoke. 1997;28:1015–1021[Abstract/Free Full Text]
  73. Sivenius J, Cunha L, Diener HC. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. Acta Neurol Scand. 1999;99:54–60[Web of Science][Medline]
  74. Z Kardiol. 1999;88:1–4[CrossRef][Medline]
  75. Leon MB, Baim DS, Popma JJ. A clinical trial comparing three antithrombotic-drug regimens after coronary-stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–1671[Abstract/Free Full Text]
  76. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb–IIIa. Lancet. 1999;353:227–231[CrossRef][Web of Science][Medline]
  77. Petronio AS, Evangelisti L, Preti R. Platelet aggregation behaviour in patients treated with ticlopidine. Drugs Exp Clin Res. 1987;13:43–50[Web of Science][Medline]
  78. Hwang JJ, Ko FN, Li YH, Ma HM, Wu GJ. Clinical implications and factors related to left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation. Cardiology. 1994;85:69–75[Web of Science][Medline]
  79. Helgason CM, Hoff JA, Kondos GT, Brace LD. Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke. 1993;24:1458–1461[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
K Gjesdal, J Feyzi, and S B Olsson
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data
Heart, February 1, 2008; 94(2): 191 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
K. T. Tan and G. Y. H. Lip
Red vs White Thrombi: Treating the Right Clot Is Crucial
Arch Intern Med, November 10, 2003; 163(20): 2534 - 2535.
[Full Text] [PDF]

Home page
 HeartHome page
S Kamath, A D Blann, B S P Chin, and G Y H Lip
Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation
Heart, September 1, 2003; 89(9): 1093 - 1095.
[Full Text] [PDF]

Home page
 HypertensionHome page
A. D. Blann, S. Nadar, and G. Y.H. Lip
Pharmacological Modulation of Platelet Function in Hypertension
Hypertension, July 1, 2003; 42(1): 1 - 7.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
B. Jilma
Surrogate markers to monitor efficacy of anticoagulants or antiplatelet drugs in atrial fibrillation
Eur. Heart J., November 2, 2002; 23(22): 1736 - 1737.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Kamath, A. D. Blann, B. S. P. Chin, F. Lanza, B. Aleil, J. P. Cazenave, and G. Y. H. Lip
A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy
Eur. Heart J., November 2, 2002; 23(22): 1788 - 1795.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Kamath, A. D. Blann, B. S. P. Chin, and G. Y. H. Lip
A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation
J. Am. Coll. Cardiol., August 7, 2002; 40(3): 484 - 490.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
S. Kamath, A. D. Blann, G. J. Caine, D. Gurney, B. S.P. Chin, and G. Y.H. Lip
Platelet P-Selectin Levels in Relation to Plasma Soluble P-Selectin and {beta}-Thromboglobulin Levels in Atrial Fibrillation
Stroke, May 1, 2002; 33(5): 1237 - 1242.
[Abstract] [Full Text] [PDF]

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kamath, S.
Right arrow Articles by Lip, G.Y.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamath, S.
Right arrow Articles by Lip, G.Y.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?